


available at www.sciencedirect.com







Introduction

This report has been constructed from the presentations made during the BDA Third Alpine Meeting which took place in Innsbruck, Austria on 14–16 March 2007.

The text has been drafted by a qualified medical writer, Mrs. Karen Eddleman BSc of Palladian Partners, Sliver Spring, MD, USA. The editorial steps taken were as follows; all documents were edited and corrected by the individual presenters of each session at the meeting. The final edit has been carried out by the Chairpersons of each session and finally by the Biotherapy Development Association (BDA) Chairman and Management Group members.

This was the third BDA Alpine Meeting which is a tri-partied event bringing together senior members of the Regulatory Authorities, FDA, EMEA, PMDA together with senior executives responsible for medicine, regulatory affairs and R&D in the oncology area from Industry plus European Patient Advocacy Group members. These all operate under the academic umbrella provided by the BDA. It is a unique event which takes place at 18 monthly intervals and the programme

contents are defined by a Scientific Steering Committee which is composed of distinguished and well-recognised authorities in each subject.

It is hoped you will find this document helpful and constructive in its content and supportive to the development of the evolution of cancer biotherapy at present and in future.

Heinz Zwierzina Mike Ellis Medizinische Universitatsklinik, Anichstrasse 35, 6020 Innsbruck, Austria

E-mail address: Heinz.Zwierzina@i-med.ac.at (Heinz)

1359-6349/\$ - see front matter © 2007 Elsevier Ltd. All rights reserved. doi:10.1016/j.ejcsup.2007.09.006